Key facts
- It has raised $31.4M.
- Notable investors include Buttonwood Group Advisors, BCM Ventures, Buttonwood Titan QC Fund, RESTEM (Biotechnology), The Brain Tumor Investment Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Diakonos Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Diakonos Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diakonos Oncology
Developer of a clinical-stage immunotherapy platform intended to focus on treating aggressive cancers. The company utilizes a proprietary double-loaded, patient-derived dendritic cell therapeutic technology to address unmet medical needs in late-stage oncology, enabling cancer treatment through targeted and personalized immune system activation.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2022
- Employees
- 14
- Website
- diakonosoncology.com/
- Ownership
- Privately Held (backing)
Diakonos Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diakonos Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diakonos Oncology in its N-PORT filings yet. We sweep new filings monthly.